This form gathers core data on IBD patients. Please complete all * marked questions. Shaded areas must be completed by clinicians and patient demographics can be completed by a non-clinical staff. A summary report will be available to download to save time in future consultations.



Attach barcode here



IBD Clinical Data sheet (v.5 22/01/19)

Patient Name: Hospital No:	Designation of person(s) extracting data: ☐ Doctor ☐ IBD Nurse ☐ Research Nurse ☐ Other (please state)
Clinical Details:	
*Is the patient NEWLY diagnosed with IBD (within the last 6 months):	☐ Yes ☐ No ☐ N/K Is the patient willing to join the more detailed INCEPTION cohort for newly diagnosed patients?
*Current IBD Diagnosis:	□ Crohn's □ UC □IBD – unspecified (IBDU) ————————————————————————————————————
*Date /year of first IBD diagnosis: (can add just year, if exact date not known)	
Level of certainty regarding diagnosis of IBD (1 = not certain; 3 = very certain)	□ 1 □ 2 □ 3
Certainty of diagnosis CD vs UC vs IBDU (1 = not certain; 3 = very certain)	□1 □2 □3
Has IBD diagnosis been confirmed by a hospit ☐ Yes ☐ No ☐ N/K ☐ Diagnostic motheds (5.4% + 1.4% +	
Diagnostic methods (indicate all relevant at the tin	me of diagnosis or used subsequently):
☐ Endoscopy ☐ Radiology ☐ Histolog☐ ☐ N/K	ogy □ Surgery

Physician's global assessment of current IBD <i>inflammatory</i> activity (i.e. on the day of BioResource blood sampling): □ Normal □ Mild □ Moderate □ Severe □ Unknown
Has the patient ever been admitted to hospital for an IBD flare? ☐ Yes ☐ No ☐ N/K
Have there been any changes in IBD diagnosis (e.g. UC to CD)?
☐ Yes ☐ No Vear of change in IBD diagnosis
Enter change in IBD diagnosis:
□ UC to CD □ IBDU – type unspecified to CD
□ CD to UC □ IBDU – type unspecified to UC
□ Other

CROHN's

*Macroscopic extent (select all that apply): NB - a frequent mistake is to assume that a patient who has had a right hemicolectomy has had colonic involvement when in fac had ileal disease: please be sure about this!	ct they just
*NB a bit of 'spill-over' inflammation in the caecum does not make it colonic. □ Oesophago-gastric □ Duodenal □ Jejunal □ Ileal □ Colonic □ Rectal	
*Ever had perianal involvement?: (Often not easy to find in medical notes - you may find it easier to ask the patient!) Yes No N/K What type of perianal lesion has the patient had? (Select all that apply): Tags / fissures / ulcers Perianal abscess Simple fistula (single fistula, little clinical problem) Complex fistula (more than one or branching or recto-vaginal or major problem) Other	
Behaviour: □B1 (inflammatory) □B2 (stenosing) □B3 (internal penetrating) *If the only fistulae have been perianal this does not reference.	make it B3
*If B3, Please specify the nature of the internal perforating / penetrating disease (Select all that apply): □Internal abscess (mesenteric, intra-abdominal, paracolic, pelvic etc) □Entero-enteric or entero-colic fistula □Entero- vesical or colo-vesical fistula □Entero- cutaneous or colo-cutaneous fistula	
□Other	
DOther *Has the patient had surgery for Crohn's? □ Yes □ No □ N/K	
*Has the patient had surgery for Crohn's? Yes NO N/K	
*Has the patient had surgery for Crohn's?	
*Has the patient had surgery for Crohn's?	
*Has the patient had surgery for Crohn's?	

ULCERATIVE COLITIS OR IBD-UNCLASSIFIED (INDETERMINATE COLITIS)

*Maximum macroscopic extent ever :
☐ Rectum ☐ Recto-sigmoid ☐ < Splenic ☐ <hepatic td="" total="" unknown<="" ☐=""></hepatic>
Maximum macroscopic extent at last assessment : ☐ Rectum ☐ Recto-sigmoid ☐ < Splenic ☐ <hepatic normal="" quiescent="" td="" throughout="" total="" unknown<="" ☐=""></hepatic>
*Has the patient undergone surgical colectomy?
□ Yes □ No □ N/K
* Date * Indication for colectomy: □ Acute severe UC □ Chronic continuous UC □ Dysplasia □ Colorectal Cancer □ N/K * Does the patient still have a rectal stump in situ? □ Yes □ No □ N/K
Has the patient undergone reconstructive surgery with an ileo-anal pouch? ☐ Yes ☐ No ☐ N/K ↓ Is the pouch still in place?
□ Yes □ No □ N/K

Extra intestinal manifestations and co-morbidities

) or No (N) – Do tick 'no' if patient has not been diagnosed with and has no symptoms equivocal, please tick 'not known'
	If No f	or all please tick here: No for all
_	osing Cholang	gitis (<i>incl PSC / AIH overlap, small duct PSC</i>):
Enteropathic ☐ Y	arthritis : ☐ N	□ N/K
Erythema No	dosum:	
□ Y	\square N	□ N/K
Iritis / uveitis	(confirmed b	y Ophthalmology):
□Y	□N	□ N/K
Orofacial Gra	nulomatosis ((oral Crohn's):
	□ N	□ N/K
Psoriasis:		
	□ N	□ N/K
Ankylosing Sp ☐ Y	oondylitis:	□ N/K
Multiple Scle		
□ Y	□N	□ N/K
Lumanhama		
Lymphoma:	□ N	□ N/K
Date	of diagnosis:	
Other maligna	-	
□ Y	□N	□ N/K
Type Date	of malignancy of diagnosis:	y:
Serious infect	ions:	
		□ N/K
Infecti Date o	ion type: (<i>spe</i> of diagnosis: _	cify e.g. TB, pneumonia)
Other (extra-inte	estinal manifestation	ons of IBD or other inflammatory/auto-immune diseases (separate with a comma):

<u>Treatment history – Please indicate which of these drugs the patient has taken</u> (Complete all that apply)

Please use the chart on the next page to select an adverse event number



Azathioprine Azathioprine Mercaptopurine Mercaptopurine Mercaptopurine Mercaptopurine Mercaptopurine Mercaptopurine Mercaptopurine Methotrexate Metho	Treatment for IBD	Year of starting	Currently on it? Y / N / NK	Year of stopping	Was the treatment effective? 1. Yes 2. Unable to assess (unable to tolerate) 3. Unable to assess (on therapeutic dose < 4 months) 4. No (on therapeutic dose >4 months - did not work) 5. Worked for <12 months then lost response 6. Worked for >12 months then lost response 7. Not known (e.g. started anti-TNF at same time, partial response only)	Significant adverse events requiring Rx cessation or dose reduction? Y / N / NK specify number(s) from chart below
Methotrexate Has the patient ever been tried on low dose thiopurine and allopurinol	· · ·	2011	N	2011	2	Y – 13 (ALT=450), 16
Has the patient ever been tried on low dose thiopurine and allopurinol _Yes _ No _ N/K Year of starting on it? Year of on it? Year of starting on it? Year of stopping on it? Year of stopping on it? Year of oliminate on the starting on it? Year of stopping on it? Year of yet on the starting on it? Year of yet on the starting on it? Year of yet on the starting on it? Year of yet on it? Year of yet on the starting on it? Year of yet on yet on it? Year of yet on	·					
Has the patient ever been tried on low dose thiopurine and allopurinol	• •					
Year of starting Vear of on it? Year of stopping 1. Year of starting Vear of starting Vear of starting Vear of on it? Vear of stopping 1. Year of starting Vear of stopping Vear of starting Vear of stopping Vear of stopping Vear of starting Vear of stopping Vear of starting Vear of s	Methotrexate					
starting on it? stopping 2. No 2. No 3. Unable to assess (e.g. had to stop due to side effects) specify number(s) from chart below Year of starting on it? Year of on it? Year of stopping 1. Yes 2. No 3. Partial (response but not remission) 4. Unable to assess (e.g. unable to tolerate) 5. Worked for < 12 months then lost response 5. Worked for < 12 months then lost response 5. Worked for < 12 months then lost response 5. Worked for < 12 months then lost response 5. Worked for < 12 months then lost response 5. Worked for < 12 months then lost response 5. Worked for < 12 months then lost response 5. Worked for < 12 months then lost response 5. Worked for < 12 months then lost response 5. Worked for < 12 months then lost response 5. Worked for < 12 months then lost response 5. Worked for < 12 months then lost response 5. Worked for < 12 months then lost response 5. Worked for < 12 months then lost response 5. Worked for < 12 months then lost response 5. Worked for < 12 months then lost response 7. Nor known 7.			on low dose	thiopurine a	and allopurinol □Yes □No □N/K	
starting on it? stopping 2. No 2. No 3. Unable to assess (e.g. had to stop due to side effects) specify number(s) from chart below Year of starting on it? Year of on it? Year of stopping 1. Yes 2. No 3. Partial (response but not remission) 4. Unable to assess (e.g. unable to tolerate) 5. Worked for < 12 months then lost response 5. Worked for < 12 months then lost response 5. Worked for < 12 months then lost response 5. Worked for < 12 months then lost response 5. Worked for < 12 months then lost response 5. Worked for < 12 months then lost response 5. Worked for < 12 months then lost response 5. Worked for < 12 months then lost response 5. Worked for < 12 months then lost response 5. Worked for < 12 months then lost response 5. Worked for < 12 months then lost response 5. Worked for < 12 months then lost response 5. Worked for < 12 months then lost response 5. Worked for < 12 months then lost response 5. Worked for < 12 months then lost response 5. Worked for < 12 months then lost response 7. Nor known 7.						
Tear of starting on it? Year of stopping on it? No 3. Partial (response but not remission) 4. Unable to assess (e.g. unable to tolerate) 5. Worked for > 12 months then lost response 6. Worked for > 12 months then lost response 7. Only at high dose / increased frequency 8. Not known Infliximab Adalimumab Golimumab Vedolizumab Ustekinumab Year of starting Year of stopping Name treatment effective? 1. Yes - (remission with no other drug used) 2. Partial (response but not remission) 3. No (did not respond despite an adequate trial of therapy) 4. Unsure (e.g. not on it for long enough, started more than one drug at same time) 5. Worked for > 12 months then lost response 7. Not known			_		 Yes No Unable to assess (e.g. had to stop due to side effects) 	Y/N/NK specify number(s) from chart
starting on it? stopping 1. Yes 2. No 3. Partial (response but not remission) 4. Unable to assess (e.g. unable to tolerate) 5. Worked for < 12 months then lost response 6. Worked for > 12 months then lost response 7. Only at high dose / increased frequency 8. Not known Infliximab Adalimumab Golimumab Vedolizumab Ustekinumab Vedolizumab Ustekinumab Year of starting On it? Year of 1. Year of 5 topping 1. Year of 5 topping 1. Year of 1.	Ciclosporin					
starting on it? stopping 1. Yes 2. No 3. Partial (response but not remission) 4. Unable to assess (e.g. unable to tolerate) 5. Worked for < 12 months then lost response 6. Worked for > 12 months then lost response 7. Only at high dose / increased frequency 8. Not known Infliximab Adalimumab Golimumab Vedolizumab Ustekinumab Vedolizumab Ustekinumab Year of starting On it? Year of 1. Year of 5 topping 1. Year of 5 topping 1. Year of 1.						
Adalimumab Golimumab Vedolizumab Ustekinumab Year of starting Year of starting Vear of stopping Vear of stopping Vear of stopping 1. Yes - (remission with no other drug used) 2. Partial (response but not remission) 3. No (did not respond despite an adequate trial of therapy) 4. Unsure (e.g. not on it for long enough, started more than one drug at same time) 5. Worked for < 12 months then lost response 6. Worked for > 12 months then lost response 7. Not known			_		1. Yes 2. No 3. Partial (response but not remission) 4. Unable to assess (e.g. unable to tolerate) 5. Worked for < 12 months then lost response 6. Worked for > 12 months then lost response 7. Only at high dose / increased frequency	Y / N / NK specify number(s) from list
Vedolizumab Ustekinumab Year of starting Vear of starting Vear of stopping 1. Yes - (remission with no other drug used) 2. Partial (response but not remission) 3. No (did not respond despite an adequate trial of therapy) 4. Unsure (e.g. not on it for long enough, started more than one drug at same time) 5. Worked for < 12 months then lost response 6. Worked for > 12 months then lost response 7. Not known	Infliximab					
Vedolizumab Vear of starting Year of stopping Year of stopping Year of stopping Year of stopping 1. Yes - (remission with no other drug used) 2. Partial (response but not remission) 3. No (did not respond despite an adequate trial of therapy) 4. Unsure (e.g. not on it for long enough, started more than one drug at same time) 5. Worked for < 12 months then lost response 6. Worked for > 12 months then lost response 7. Not known						
Vear of starting on it? Year of stopping on it? Year of stopping on it? Was the treatment effective? 1. Yes - (remission with no other drug used) 2. Partial (response but not remission) 3. No (did not respond despite an adequate trial of therapy) 4. Unsure (e.g. not on it for long enough, started more than one drug at same time) 5. Worked for < 12 months then lost response 6. Worked for > 12 months then lost response 7. Not known						
Year of starting On it? Year of stopping Year of stopping Year of stopping 1. Yes - (remission with no other drug used) 2. Partial (response but not remission) 3. No (did not respond despite an adequate trial of therapy) 4. Unsure (e.g. not on it for long enough, started more than one drug at same time) 5. Worked for < 12 months then lost response 6. Worked for > 12 months then lost response 7. Not known						
starting on it? 1. Yes - (remission with no other drug used) 2. Partial (response but not remission) 3. No (did not respond despite an adequate trial of therapy) 4. Unsure (e.g. not on it for long enough, started more than one drug at same time) 5. Worked for < 12 months then lost response 6. Worked for > 12 months then lost response 7. Not known	Ustekinumab					
starting on it? 1. Yes - (remission with no other drug used) 2. Partial (response but not remission) 3. No (did not respond despite an adequate trial of therapy) 4. Unsure (e.g. not on it for long enough, started more than one drug at same time) 5. Worked for < 12 months then lost response 6. Worked for > 12 months then lost response 7. Not known						
Mesalazine (5 ASA)	Manufacina (5.464)		_		1. Yes - (remission with no other drug used) 2. Partial (response but not remission) 3. No (did not respond despite an adequate trial of therapy) 4. Unsure (e.g. not on it for long enough, started more than one drug at same time) 5. Worked for < 12 months then lost response 6. Worked for > 12 months then lost response	Y / N / NK specify number(s) from list
	iviesalazine (5 ASA)					

	Year of starting	Currently on it?	Year of stopping	Was the treatment effective? 1. Yes 2. No 3. Initially responded then lost response 4. Unable to assess (e.g. unable to tolerate) 5. Not known	Significant adverse events? Y / N / NK specify number(s) from list below
Oral steroids (prednisolone or budesonide)					

	Year of starting	Currently on it?	Year of stopping	Was the treatment effective? 1. Yes (no 'rescue' therapy needed) 2. No (required additional rescue therapy) 3. Unable to assess (e.g. unable to tolerate) 4. Not known	Significant adverse events? Y / N / NK specify number(s) from list below
IV steroids					

	Year of starting	Currently on it?	Year of stopping	Was the treatment effective? 1, Yes 2, No 3, Partial (response but not remission) 5, Not known	Significant adverse events? Y / N / NK specify number(s) from list below
Tofacitinib					
Any other drug? (what)					

Please use the numbers in this table to complete the significant adverse events column in the treatment history tables above

Adverse Event	Adverse Event	Adverse Event
1. Abdominal pain	14. Injection site reaction	27. Psychosis
2. Anaemia	15. Interstitial nephritis	28. Rash
3. Anaphylaxis or anaphylactoid reaction	16. Joint pain	29. Raised lipids
4. Could not tolerate	17. Leucopaenia a) Minimum white cell count b) Minimum neutrophil count	30. Renal Impairment
5 Demyelination or other neurological symptoms	18. Malaise	31. Sepsis
6. Diarrhoea	19. Nasopharyngitis	32. Thrombocytopenia
7. Deranged LFTs a) Maximum ALT b) Maximum ALP c) Maximum bilirubin	20. Nausea / vomiting	34. Other
8. Exacerbation of IBD symptoms	21. Neutropaenia a) Minimum white cell count b) Minimum neutrophil count	34. Not known
9 Fever	22. None	
10. Flu-like symptoms	23. Osteopenia	
11. Hypertension	24. Pancreatitis a) maximum amylase b) maximum lipase	
12. Hypotension	25.Pancytopaenia	
13. Infection a) bacterial b) viral c) TB / Tuberculosis d) Other / not known	26.Psoriasis	

Demographics (Section to be completed by research staff)

*Smoking status at DIAGNOSIS (please tick one option):
□ Never smoked
□ Not known
□ Smoking at diagnosis:
*Roughly how many cigarettes was the patient smoking at the time of diagnosis?
□ Less than 5 □ 5+ □ Pipe only □ N/K
* Had quit before diagnosis:
Roughly how long before diagnosis did patient quit smoking? □ Less than 1 month □ 1-6 months □ More than 6 months □ N/K
CURRENT smoking status:
□Not smoking □Smoking □Other □Not known
<u> </u>
Family history of IBD?
↓ Which relative? Which type of IBD? Relative name (if participant willing to share)?
,,
Alongside IBD BioResource there are two parallel projects with overlapping objectives – please identify which of these parallel projects the patient has signed consent for:
☐ PrediCCt ☐ IBD Registry
Has the IBD BioResource consent been signed? **This section is a vital field for NIHR accrual data**:
□ Y □ N
Data of assessed
Date of consent:
Which version of consent form has been used?: \Box 1 \Box 2 \Box 2.1 \Box 3 \Box 4 \Box 5

Date of most recent clinic review (i.e. when were data re clinical features last updated?):
Please enter the patient's UK IBD Genetics Consortium identifier number (if known): If entering multiple numbers, please separate with a comma in REDCap
Has the patient withdrawn from the IBD BioResource study?
□ Y □ N □ N/K
Withdrawal status?
☐ Withdrawn with no participation
☐ Withdrawn with no participation and data removed
□ Deceased
□ Other
Date withdrawal requested:
Date of actual withdrawal:
Withdrawal form ID number:
Withdrawn by:
Other studies notified (IBD Registry, PrediCCt):
□ Y □ N □ N/K